Multiple lots of the weight-loss medication Wegovy, manufactured by Novo Nordisk, have been recalled due to the discovery of hair in prefilled syringes. This information was confirmed through two notices published by the Food and Drug Administration (FDA) on December 31, 2023. The recall involves specific batches of Wegovy, which contains the active ingredient semaglutide.
The FDA’s first notice highlights the recall of four lots of Wegovy single-dose prefilled pens containing 0.5 mg/0.5 mL doses. In a second notice issued on the same day, the agency also reported that four additional lots of Wegovy prefilled pens at 1 mg/0.5 mL doses are affected by the same issue.
According to the FDA, the recall was initiated due to the “presence of particulate matter” within the syringes, specifically noting the presence of hair. Such contamination raises serious health concerns, as the integrity and safety of injectable medications are critical for patient safety.
While the FDA has not reported any adverse events related to this contamination, the agency urges patients and healthcare providers to be vigilant. Individuals in possession of the affected lots are advised to return the products to the place of purchase or contact their healthcare provider for guidance.
Wegovy, which has gained popularity as a weight-loss treatment, has been subject to scrutiny in recent months due to supply chain issues and an increase in demand. This recall adds another layer of concern for patients relying on the medication for weight management.
Both the FDA and Novo Nordisk emphasize the importance of quality control and patient safety. The company has stated that it is taking this matter seriously and is working to resolve the issue promptly.
Patients and healthcare professionals are encouraged to check the lot numbers of their Wegovy pens to determine if they are affected by the recall. The FDA has provided a detailed list of the affected lot numbers on its website, assisting consumers in identifying the recalled products.
As the situation develops, further updates from Novo Nordisk and the FDA are anticipated. Ensuring the safety of medications remains a top priority for both organizations, and they continue to monitor the situation closely to protect public health.
